This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
PetIQ, Inc. (PETQ) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
PetIQ (PETQ) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Atea Pharmaceuticals, Inc. (AVIR) and PetIQ (PETQ) have performed compared to their sector so far this year.
Boston Scientific Corporation (BSX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Fast-paced Momentum Stock PetIQ (PETQ) Is Still Trading at a Bargain
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, PetIQ (PETQ) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
PetIQ (PETQ) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
PetIQ (PETQ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is Abivax SA Sponsored ADR (ABVX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Abivax SA Sponsored ADR (ABVX) and PetIQ (PETQ) have performed compared to their sector so far this year.
Should Value Investors Buy PetIQ (PETQ) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PetIQ, Inc. (PETQ) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
PetIQ (PETQ) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PetIQ (PETQ) Tops Q2 Earnings Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of 42.86% and 12.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
SurModics (SRDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 12.90% and 0.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Fast-paced Mover PetIQ (PETQ) Is a Great Choice for Value Investors
by Zacks Equity Research
PetIQ (PETQ) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Wall Street Analysts See a 40.44% Upside in PetIQ (PETQ): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 40.4% upside potential for PetIQ (PETQ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Are Investors Undervaluing PetIQ (PETQ) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Entera Bio Ltd. (ENTX) and PetIQ (PETQ) have performed compared to their sector so far this year.
Despite Fast-paced Momentum, PetIQ (PETQ) Is Still a Bargain Stock
by Zacks Equity Research
PetIQ (PETQ) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Wall Street Analysts See a 45.22% Upside in PetIQ (PETQ): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for PetIQ (PETQ) points to a 45.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is PetIQ (PETQ) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Value Stocks to Buy for May 20th
by Zacks Equity Research
SGRP, PETQ and GOOS made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 20, 2024.
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
PetIQ's (PETQ) first-quarter results are likely to reflect growth in the Product and Services segments of the business.
Baxter International (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 6.56% and 1.20%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Is PetIQ (PETQ) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts Think PetIQ (PETQ) Could Surge 76.18%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 76.2% in PetIQ (PETQ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
PetIQ, Inc. (PETQ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
PetIQ (PETQ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
PetIQ (PETQ) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
PetIQ (PETQ) concluded the recent trading session at $18.23, signifying a -0.87% move from its prior day's close.
Should Value Investors Buy PetIQ (PETQ) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.